In this article NOVO.B-DKLLYWWGWW Follow your favorite stocks CREATE FREE ACCOUNTAn injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.
But will Americans trust the most iconic brand in the legacy weight-loss business to guide them into its future?
"Big pharma was coming for weight loss, and if they didn't have a clinical angle, they would have run the risk of becoming an irrelevant company."
"This is a new, incredibly powerful and effective class of pharmaceuticals that a lot of people will find help improve their health."
watch nowRisks of overreliance on obesity drugs The risk is real that providers may use the medications and "forget about lifestyle," said John Batsis, an associate professor and nutrition expert at the University of North Carolina Chapel Hill's school of public health.
Persons:
Eli Lilly’s, Brendan Mcdermid, Eli Lilly, —, Sima Sistani —, Sistani, Alex Fuhrman, Hallum, Fuhrman, Davidson, Linda Bolton Weiser, I've, Geoff Cook, Cook, John Batsis, Batsis
Organizations:
Reuters, Novo Nordisk, CNBC, Craig, pharma, University of North, University of North Carolina Chapel
Locations:
New York City, U.S, Herbalife, University of North Carolina